Stay updated on KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial
Sign up to get notified when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.

Latest updates to the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing the previous v3.4.1. This update does not alter study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check22 days agoChange DetectedA minor platform revision entry was added: Revision: v3.4.1, replacing the previous v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check36 days agoChange DetectedIntroduced a glossary display option (Show glossary) and updated page metadata to show 'Last Update Submitted that Met QC Criteria' and Revision: v3.4.0. The previous QC label usage and 'No FEAR Act Data' wording were adjusted.SummaryDifference0.1%

- Check43 days agoChange DetectedRevision label changed from v3.3.3 to v3.3.4. This appears to be a minor metadata update with no changes to the study content, eligibility criteria, or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check71 days agoChange DetectedThe study’s locations were updated: new site regions across the United States and internationally were added, and several prior location groups were removed, reflecting an updated site network (revision: v3.3.3).SummaryDifference2%

- Check92 days agoChange DetectedRevision history updated to include Revision: v3.3.2 and remove Revision: v3.3.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.